Literature DB >> 21349461

Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool.

Yoshihiro Morino1, Mitsuru Abe, Takeshi Morimoto, Takeshi Kimura, Yasuhiko Hayashi, Toshiya Muramatsu, Masahiko Ochiai, Yuichi Noguchi, Kenichi Kato, Yoshisato Shibata, Yoshikazu Hiasa, Osamu Doi, Takehiro Yamashita, Tomoaki Hinohara, Hiroyuki Tanaka, Kazuaki Mitsudo.   

Abstract

OBJECTIVES: This study sought to establish a model for grading lesion difficulty in interventional chronic total occlusion (CTO) treatment.
BACKGROUND: Owing to uncertainty of success of the procedure and difficulties in selecting suitable cases for treatment, performance of interventional CTO remains infrequent.
METHODS: Data from 494 native CTO lesions were analyzed. To eliminate operator bias, the objective parameter of successful guidewire crossing within 30 min was set as an end point, instead of actual procedural success. All observations were randomly assigned to a derivation set and a validation set at a 2:1 ratio. The J-CTO (Multicenter CTO Registry of Japan) score was determined by assigning 1 point for each independent predictor of this end point and summing all points accrued. This value was then used to develop a model stratifying all lesions into 4 difficulty groups: easy (J-CTO score of 0), intermediate (score of 1), difficult (score of 2), and very difficult (score of ≥ 3).
RESULTS: The set end point was achieved in 48.2% of lesions. Independent predictors included calcification, bending, blunt stump, occlusion length >20 mm, and previously failed lesion. Easy, intermediate, difficult, and very difficult groups, stratified by J-CTO score, demonstrated stepwise, proportioned, and highly reproducible differences in probability of successful guidewire crossing within 30 min (87.7%, 67.1%, 42.4%, and 10.0% in the derivation set and 92.3%, 58.3%, 34.8%, and 22.2% in the validation set, respectively). Areas under receiver-operator characteristic curves were comparable (derivation: 0.82 vs. validation: 0.76).
CONCLUSIONS: This model predicted the probability of successful guidewire crossing within 30 min very well and can be applied for difficulty grading.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21349461     DOI: 10.1016/j.jcin.2010.09.024

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  137 in total

1.  Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft.

Authors:  Kenichi Sakakura; Masataka Nakano; Fumiyuki Otsuka; Kazuyuki Yahagi; Robert Kutys; Elena Ladich; Aloke V Finn; Frank D Kolodgie; Renu Virmani
Journal:  Eur Heart J       Date:  2013-10-14       Impact factor: 29.983

2.  Revascularization of right coronary artery chronic total occlusion by bilateral knuckle technique.

Authors:  Liang Guo; Qigang Guan
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 3.  Practical utilization of cardiac computed tomography for the success in complex coronary intervention.

Authors:  Kenji Sadamatsu; Masaaki Okutsu; Satoru Sumitsuji; Tomohiro Kawasaki; Sunao Nakamura; Yoshihiro Fukumoto; Kenichi Tsujita; Shinjo Sonoda; Yoshio Kobayashi; Yuji Ikari
Journal:  Cardiovasc Interv Ther       Date:  2021-01-11

Review 4.  A contemporary review of clinical significances of percutaneous coronary intervention for chronic total occlusions, with some Japanese insights.

Authors:  Yoshihiro Morino
Journal:  Cardiovasc Interv Ther       Date:  2021-03-03

Review 5.  Approach to CTO Intervention: Overview of Techniques.

Authors:  Aris Karatasakis; Barbara Anna Danek; Dimitri Karmpaliotis; Khaldoon Alaswad; Minh Vo; Mauro Carlino; Mitul P Patel; Stéphane Rinfret; Emmanouil S Brilakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

6.  Bioresorbable vascular scaffolds in coronary chronic total occlusions revascularization: safety assessment related to struts coverage and apposition in 6-month OCT follow-up.

Authors:  Rosa Alba Abellas-Sequeiros; Raymundo Ocaranza-Sanchez; Ramiro Trillo-Nouche; Carlos Gonzalez-Juanatey; Jose Ramon Gonzalez-Juanatey
Journal:  Heart Vessels       Date:  2017-04-21       Impact factor: 2.037

7.  Intravascular ultrasound guidance of percutaneous coronary intervention in ostial chronic total occlusions: a description of the technique and procedural results.

Authors:  Nicola Ryan; Nieves Gonzalo; Philip Dingli; Oscar Vedia Cruz; Pilar Jiménez-Quevedo; Luis Nombela-Franco; Ivan Nuñez-Gil; María Del Trigo; Pablo Salinas; Carlos Macaya; Antonio Fernandez-Ortiz; Javier Escaned
Journal:  Int J Cardiovasc Imaging       Date:  2017-02-14       Impact factor: 2.357

8.  "Spiral stenting"-creating a subintimal neo-luminal helix around a massively calcified ostial chronic total occlusion of the right coronary artery in a patient with recurrent ventricular tachycardia.

Authors:  Kambis Mashayekhi; Zivile Valuckiene; Hans Neuser; Marlon Walter; Wolfgang Gappmaier; Thomas Kaiser; Franz-Josef Neumann; Ibrahim Akin; Michael Behnes
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

9.  A Novel Risk Score in Predicting Failure or Success for Antegrade Approach to Percutaneous Coronary Intervention of Chronic Total Occlusion: Antegrade CTO Score.

Authors:  Mohammad Hasan Namazi; Ali Reza Serati; Hosein Vakili; Morteza Safi; Saeed Ali Pour Parsa; Habibollah Saadat; Maryam Taherkhani; Sepideh Emami; Shamseddin Pedari; Masoomeh Vatanparast; Mohammad Reza Movahed
Journal:  Int J Angiol       Date:  2016-10-31

Review 10.  Role of Percutaneous Chronic Total Occlusion Interventions in Patients with Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction.

Authors:  Nayef A Abouzaki; Jose E Exaire; Luis A Guzmán
Journal:  Curr Cardiol Rep       Date:  2018-10-01       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.